Vanda Pharmaceuticals (VNDA) Gross Margin (2010 - 2026)
Vanda Pharmaceuticals recorded quarterly Gross Margin of 93.89% in Q1 2026, up 0.63% quarter-over-quarter from 93.3% in Q4 2025, and up 93.0% year-over-year from 48.65% in Q1 2025.
Vanda Pharmaceuticals' Gross Margin history runs 14 years deep, the most recent figure standing at 93.89% for Q1 2026.
- In Q1 2026, Gross Margin rose 93.0% year-over-year to 93.89%; the TTM figure through Mar 2026 stood at 94.18% (down 16.0% YoY), while the FY2025 annual figure was 93.96%, down 34.0% from the prior year.
- Gross Margin came in at 93.89% for Q1 2026 at Vanda Pharmaceuticals, up from 93.3% in the prior quarter.
- In the past five years, Gross Margin ranged from a high of 95.13% in Q4 2024 to a low of 90.32% in Q3 2022.
- A 5-year average of 92.82% and a median of 92.75% in 2024 frame the typical range for Gross Margin.
- Across the five-year window, Gross Margin soared 277 bps in 2024 and tumbled 183 bps in 2025, its largest moves.
- Vanda Pharmaceuticals' Gross Margin stood at 90.33% in 2022, then rose by 2 bps to 92.36% in 2023, then advanced by 3 bps to 95.13% in 2024, then decreased by 2 bps to 93.3% in 2025, then grew by 1 bps to 93.89% in 2026.
- According to Business Quant data, Gross Margin over the past three periods registered 93.89%, 93.3%, and 94.75% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 79.04% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 86.85% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 91.79% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 82.22% |
| 10 | Vanda Pharmaceuticals | 379.35 Mn | 177.04 Mn | 48.56 Mn | 93.89% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 93.89% |
| Dec 31, 2025 | 93.30% |
| Sep 30, 2025 | 94.75% |
| Jun 30, 2025 | 94.80% |
| Mar 31, 2025 | 92.96% |
| Dec 31, 2024 | 95.13% |
| Sep 30, 2024 | 94.65% |
| Jun 30, 2024 | 94.59% |
| Mar 31, 2024 | 92.75% |
| Dec 31, 2023 | 92.36% |
| Sep 30, 2023 | 92.11% |
| Jun 30, 2023 | 92.40% |
| Mar 31, 2023 | 92.36% |
| Dec 31, 2022 | 90.33% |
| Sep 30, 2022 | 90.32% |
| Jun 30, 2022 | 90.59% |
| Mar 31, 2022 | 90.59% |
| Dec 31, 2021 | 90.83% |
| Sep 30, 2021 | 90.30% |
| Jun 30, 2021 | 90.33% |
| Mar 31, 2021 | 90.38% |
| Dec 31, 2020 | 90.52% |
| Sep 30, 2020 | 90.22% |
| Jun 30, 2020 | 90.60% |
| Mar 31, 2020 | 91.02% |
| Dec 31, 2019 | 89.78% |
| Sep 30, 2019 | 88.60% |
| Jun 30, 2019 | 89.22% |
| Mar 31, 2019 | 89.28% |
| Dec 31, 2018 | 89.32% |
| Sep 30, 2018 | 89.69% |
| Jun 30, 2018 | 88.99% |
| Mar 31, 2018 | 89.54% |
| Dec 31, 2017 | 89.18% |
| Sep 30, 2017 | 89.05% |
| Jun 30, 2017 | 89.23% |
| Mar 31, 2017 | 89.30% |
| Dec 31, 2016 | 86.21% |
| Sep 30, 2016 | 81.84% |
| Jun 30, 2016 | 81.98% |
| Mar 31, 2016 | 82.09% |
| Dec 31, 2015 | 80.62% |
| Sep 30, 2015 | 77.03% |
| Jun 30, 2015 | 79.10% |
| Mar 31, 2015 | 77.36% |
| Dec 31, 2014 | 95.56% |
| Sep 30, 2014 | 95.24% |
| Jun 30, 2014 | 98.18% |
| Dec 31, 2010 | 100.00% |
| Sep 30, 2010 | 100.00% |
| Jun 30, 2010 | 1.69% |